Illumina’s Legal Triumph Limits EU Merger Control
Illumina defeats EU in court, curbing merger scrutiny and blocking a $432M fine over Grail acquisition.
- Latest
- Trending
Illumina defeats EU in court, curbing merger scrutiny and blocking a $432M fine over Grail acquisition.
Chinese and US scientists unveil ActFound, an AI model helping optimize drug development by predicting bioactivity efficiently.
NHG integrates AI for lung, heart screening, enhancing radiology workflow efficiency and patient care.
Biotech firms restructure with layoffs as FDA approves new drugs, exemplifying industry challenges and opportunities.
Adaptimmune's Tecelra launch marks progress in cell therapy, with strong Q2 financials and strategic plans for cancer treatment.
Federal push to harness AI in medical research relies on extensive data collection and privacy safeguards.
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
iCAD's Q2 revenue increased by 21% as the company shifts to a cloud-based SaaS model, aiming for enhanced profitability.
Cathie Wood seizes volatility by investing in Amazon, Roku, and Guardant Health for potential growth amidst market fluctuations.
Exploring the impact of AI bias in healthcare and solutions to ensure equitable patient care.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.